Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Key Inclusion Criteria: * Histologically confirmed, stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer * Platinum-resistant or -sensitive subjects after completing first-line treatment (debulking surgery and adjuvant or neoadjuvant treatment with standard of care treatment such as carboplatin and paclitaxel). Subjects may have had any number of subsequent lines of chemotherapy. * Must have evidence of progressive disease with either biochemical (i.e. rising CA-125) and/or radiologic progression * Must have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy, and be willing to undergo tumor biopsy during treatment * Ambulatory with an ECOG 0-1 * Life expectancy ≥ 6 months * Meet protocol-specified laboratory requirements Key Exclusion Criteria: * Eligible for otherwise curative treatment or undergoing concurrent therapy * Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor * Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer * Clinical ascites * Any single lesion greater than or equal to 4 cm (per RECIST v1.1) * Malignant bowel obstruction * History of autoimmune disease requiring treatment within the last two years (except vitiligo or diabetes) * Recent history of thyroiditis * Presence of a serious acute infection or chronic infection * Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases) * GI condition that might limit absorption of oral agents * Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months * Ongoing treatment with steroid therapy or other immunosuppressive * Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors * Receipt of live attenuated vaccines * Acute or chronic skin and/or microvascular disorders * Edema or lymphedema in the lower limbs \> grade 2